A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.
Marco Solmi, Chaomei Chen, Charles Dauré, Anne Buot, Michael Ljuslin, Vincent Verroust, Luc Mallet, Yasser Khazaal, Stéphane Rothen, Gabriel Thorens, Daniele Zullino, Gabriella Gobbi, Joshua D. Rosenblat, Muhammad Ishrat Husain, Danilo de Gregorio, David Castle, Michel Sabé
European Neuropsychopharmacology November 1, 2022 DOI: 10.1016/j.euroneuro.2022.09.004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scientometric analysis Peer reviewed |
|---|---|
| Sample size | 31,687 |
| Population | Publications on psychedelics in Web of Science Core Collection up to March 18, 2022 |
| Keywords | Bibliometrix Citespace Evidence synthesis Mood disorders New psychoactive substances Psychedelic research Mental health therapeutics Drug development Psychopharmacology Clinical trials |
| Citations | 55 |
| Key points | Psychedelic research has undergone a translational evolution from bench to bedside, marked by a 'psychedelic renaissance' after the 1990s, leading to approval of esketamine for depression and likely future approvals for other psychedelics. |
Abstract
A scientometric analysis was realized to outline clinical research on psychedelics over the last century. Web of Science Core Collection was searched up to March 18, 2022, for publications on psychedelics. Network analyses and bibliometrics were combined, to identify research themes and trends with Bibliometrix and CiteSpace. The primary aim was to measure research trends evolution over time, and the secondary aims were to identify bibliometric performance and influence networks of publications, authors, institutions, and countries. Sensitivity analyses were conducted for 2016-2022, and 2021 time periods. We included 31,687 documents (591,329 references), which aggregated into a well-structured network with credible clustering. Research productivity was split into an early less productive period mainly focusing on safety issues, and a "psychedelic renaissance" after the 1990s. Major trends were identified for hallucinogens/entheogens, entactogens, novel psychoactive substances (NPS), and on dissociative substances. There was a translational evolution from the bench to the bedside, with phase 2 and 3 trials and/or evidence synthesis in particular. The most recent trends concerned NPS, ketamine-associated brain changes, and ayahuasca-assisted psychotherapy. The USA and Canada were the most productive settings for the research overall, and more recently this geographical distribution became more prominent, reflecting legislative context/policy making. A translational evolution of psychedelics has been occurring, that has brought approval of esketamine for depression and will likely lead to approval of additional psychedelics across mental and physical conditions. Toxicology screening tools for NPS are urgently needed, which in turn might follow the same translational evolution of psychedelics in the future.
Citations in the library
Cited by 33
- Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies European Neuropsychopharmacology August 7, 2023
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry March 1, 2025
- Stimulant and hallucinogenic novel psychoactive substances; an update Expert Review of Clinical Pharmacology November 2, 2023
- Psilocybin’s effects on cognition and creativity: A scoping review Journal of Psychopharmacology July 1, 2023
- Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry February 1, 2025
and 28 more in the library
Cites 67
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 62 more in the library